The finding of the selection of mutant BRAF alleles in melanoma progression appears to be significant in view of the recent development of selective BRAFV600E kinase inhibitors (Sala et al, 2008; Tsai et al, 2008) that showed successful preliminary clinical results (Flaherty et al, 2010). The gene discussed is BRAF; the disease is melanoma.